Replies to post #225952 on Biotech Values

[jellybean]

IMO, the biotech market has become exponentially more illogical possibly driven by the sheer number of companies that has diluted the focus of serious investors. The depth and persistence of misinformation astounds me, and I think the volatility provides a hiding place for the more nefarious investors.

[DewDiligence]

BLCM +41%(!?) on opt-in by M.D. Anderson:

https://finance.yahoo.com/news/bellicum-pharmaceuticals-licenses-caspacide-safety-123010774.html

Under terms of the original license agreement, MD Anderson’s decision to exercise the option entitled Bellicum to receive an upfront payment of $5 million, to be recognized in the fourth quarter 2019 financial results, and undisclosed future milestone payments and royalties on sales. The license agreement with Bellicum specifically covers use of the CaspaCIDe safety switch in MD Anderson’s CD19-directed chimeric antigen receptor natural killer (CAR NK) cell construct.